Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.
The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.
How to buy shares in Bolt Biotherapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BOLT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Bolt Biotherapeutics stock price (NASDAQ: BOLT)Use our graph to track the performance of BOLT stocks over time.
Bolt Biotherapeutics shares at a glance
|Latest market close||$3.76|
|52-week range||$3.43 - $43.07|
|50-day moving average||$6.70|
|200-day moving average||$14.00|
|Wall St. target price||$22.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.20|
Buy Bolt Biotherapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Bolt Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bolt Biotherapeutics price performance over time
|1 week (2022-01-13)||-0.79%|
|1 month (2021-12-22)||-16.63%|
|3 months (2021-10-22)||-71.05%|
|6 months (2021-07-22)||-70.72%|
|1 year (2021-01-18)||N/A|
|2 years (2020-01-18)||N/A|
|3 years (2019-01-18)||N/A|
|5 years (2017-01-18)||N/A|
Bolt Biotherapeutics financials
|Gross profit TTM||$-40,126,000|
|Return on assets TTM||-26.13%|
|Return on equity TTM||-64.71%|
|Market capitalisation||$147.6 million|
TTM: trailing 12 months
Bolt Biotherapeutics share dividends
We're not expecting Bolt Biotherapeutics to pay a dividend over the next 12 months.
Bolt Biotherapeutics overview
Bolt Biotherapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Bolt Biotherapeutics is owned by insiders or institutions?
Currently 6.667% of Bolt Biotherapeutics shares are held by insiders and 94.869% by institutions. How many people work for Bolt Biotherapeutics?
Latest data suggests 65 work at Bolt Biotherapeutics. When does the fiscal year end for Bolt Biotherapeutics?
Bolt Biotherapeutics's fiscal year ends in December. Where is Bolt Biotherapeutics based?
Bolt Biotherapeutics's address is: 900 Chesapeake Drive, Redwood City, CA, United States, 94063 What is Bolt Biotherapeutics's ISIN number?
Bolt Biotherapeutics's international securities identification number is: US0977021049
More guides on Finder
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert